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Pseudoexons occur frequently in the human ge-
nome. This paper characterizes a pseudoexon in
the GH receptor gene. Inappropriate activation of
this pseudoexon causes Laron syndrome. Using in
vitro splicing assays, pseudoexon silencing was
shown to require a combination of a weak 5
pseudosplice-site and splicing silencing elements
within the pseudoexon. Immunoprecipitation ex-
periments showed that specific binding of heter-
ogenous nuclear ribonucleoprotein E1 (hnRNP E1)
and U1 small nuclear ribonucleoprotein (snRNP) in
the pre-spliceosomal complex was associated
with silencing of pseudoexon splicing. The possi-
ble role of hnRNP E1 was further supported by RNA
interference experiments in cultured cells. Immu-
noprecipitation experiments with three other
pseudoexons suggested that pre-spliceosomal
binding of U1 snRNP is a potential general mech-
anism of suppression of pseudoexons. (Molecular
Endocrinology 21: 2529–2540, 2007)
SPLICING IS THE process by which introns areprecisely identified and excised with the exons
ligated to form a translatable message. Alternative
splicing is the process whereby alternative exons are
selected from an identical pre-mRNA to give rise to
two or more different mRNAs, which in turn leads to
translation into different proteins. The process of al-
ternative splicing allows a single gene to code for
multiple products, thus creating an additional level of
diversity and complexity.
Understanding the regulation of splicing and alter-
native splicing is particularly pertinent to endocrinol-
ogy. Firstly, both hormones and their receptors are
subject to alternative splicing which adds a further
level of complexity to the endocrine regulation of gene
expression, see review (1). Secondly, splicing defects
are highly represented in inherited endocrine condi-
tions, for example in congenital adrenal hyperplasia
due to 21-hydroxylase deficiency (CYP21) (2, 3), mul-
tiple endocrine neoplasia type 1 (MENIN) (4), and they
are the most common type of defect in neurofibroma-
tosis type 1 (5). Thirdly, splicing defects are commonly
found in all types of cancer (6–8) and, in particular, in
inherited cancer syndromes (9–11).
However, although the process of splicing itself is
relatively well understood (see reviews in Refs. 1, 12,
and 13), the mechanisms by which the cellular ma-
chinery correctly identifies exons is not clear. It is, at
least in part, dependent on loosely defined sequences
termed splice sites.
Splice-site sequences that do not undergo splic-
ing are termed pseudosites (see Ref. 14). In the
human hprt gene, pseudosites outnumber their gen-
uine counterparts by several hundred and, in turn,
define a set of pseudoexons that outnumber the
genuine exons by a factor of ten (15). It has been
shown that one in three random restriction frag-
ments of human genomic DNA contain splicing si-
lencing properties compared with only one in 27
fragments of E. coli DNA (16), and computational
analysis suggests that pseudoexons are associated
with a 20% greater frequency of silencing elements
than non-pseudoexon-containing intronic regions
(17). However, the mechanism for pseudoexon skip-
ping has only been determined for one pseudoexon
in the ATM pre-mRNA, where the spliceosomal
component U1 small nuclear ribonucleoprotein (U1
snRNP) was found to have a role (18). The intronic
elements suppressing pseudoexon splicing have
also been described for one randomly chosen
pseudoexon in the human hprt gene (15).
The GH receptor (GHR) pseudoexon (19) is one of
several pseudoexons that have been shown to
cause disease when activated (Table 1). It under-
goes efficient splicing when there is a single point
mutation (A to G at the last nucleotide of the
pseudoexon). This in turn results in the addition of
36 amino acids to the GHR leading to defective
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trafficking and the syndrome of GH insensitivity
(Laron syndrome) (20). Affected patients have a
variable phenotype despite harboring the same mu-
tation (21). The point mutation changes the se-
quence of the pseudosplice-site from TCA/gtgagc
(where the slash indicates the exon/intron boundary)
to TCG/gtgagc. When the GHR pseudoexon is
placed in a well-characterized splicing reporter
(AdML-par, derived from the Adenovirus Major Late
gene), it behaves in an in vitro splicing system as it
does in vivo (19). To understand the mechanism of
GHR pseudoexon suppression, we based experi-
ments on in vitro splicing assays, immunoprecipita-
tions, and in vivo splicing assays in cultured
HeLa cells.
RESULTS
The Wild-Type GHR Pseudoexon 5 Splice Site Is
Not Intrinsically Defective
A bio-informatic analysis using SpliceSiteFinder (http://
www.genet.sickkids.on.ca/ali/splicesitefinder.html) was
performed to assess the theoretical strengths of the
pseudoexon splicing sites. This showed that the combined
scores for theGHRpseudoexonbranch site and splice-site
scores was greater than four of the eight constitutive GHR
exons, including the downstream exon 7 (Table 2). This
indicated that theoretical splice-site scores alone had little
predictive value for the GHR pseudoexon. However, we
note that the A to Gmutation leads to an increase in the 5
Table 1. Genetic Diseases Caused by Pseudoexon Activation
Genetic Disease Mutation and Location Possible Mechanism of Activation
Cystic fibrosis (60, 61) C to T (intron 19, CFTR), A to G (intron
11, CFTR)
Activation of 5 pseudosites
Neurofibromatosis type II (62) G to A (intron 5, NF2) Creation of a branchpoint upstream of
a pseudoexon
Mucopolysaccharidosis type VII (63) TC deletion (intron 8, and 
glucoronidase)
Activation of a 5 pseudosite
Haemophilia A (64) A to G (intron 1, factor VIII) Activation of a 5 pseudosite
Neurofibromatosis type I (5) A to G (intron 30, NF1) Activation of a 5 pseudosite
X-linked Hypophosphataemia (30) G to T (intron 7, PHEX) Activation of a 5 pseudosite
GH Insensitivity (19) A to G (intron 6, GHR) Activation of a 5 pseudosite
Ataxia Telangectasia (18) GTAA deletion (intron 20, ATM) Loss of U1 snRNP binding site
Becker muscular dystrophy (65) A to G (intron 62, DMD) A to G (intron
25, DMD)
Activation of a 5 pseudosite activation
of a 3 pseudosite
Human pseudoexons have been shown to cause disease when naturally occurring mutations occur. The genetic disease caused,
the nature of the mutation, and its location, together with the likely mechanism of pseudoexon activation, are shown. Only for the
GHR (19) and ATM (18) pseudoexons have splicing experiments been performed to confirm that the mutation is necessary and
sufficient for activation.
Table 2. GHR Exon and Pseudoexon Splice Site Scores
GHR Exon or
Pseudoexon
Length
(Nucleotides)
3 Splice
Site Score
Branch Site
Score
5 Splice
Site Score
3 , 5, and
Branch Score
1 32 69.5
2 81 94.1 81 88.9 264
3 66 65.6 89.2 81.9 236.7
4 130 95.4 98.0 65.3 258.7
5 173 83.9 81.0 85.6 250.5
6 179 74.7 97.1 86.5 258.3
7 166 84 83.9 79.9 247.8
8 91 87.9 62.6 89.2 239.7
9 70 81.6 71.6 85.8 239
10 3425 90 74
WT 108 81.6 97.1 70.3 249
MT 108 81.6 97.1 82.7 261.4
Splice-site scores for the 10 exons of the GHR and scores for wild-type (WT) and mutant (MT) pseudoexons. The table shows
individual scores for the splice sites and branch point and the total combined scores. The scores that are lower than the wild-type
pseudoexon are shown in bold. Scores for 3 and 5 splice sites and branch sites were calculated using Alex Dong Li’s
SpliceSiteFinder (http://www.genet.sickkids.on.ca/ali/splicesitefinder.html). This algorithm for splice-site scores is based on the
Shapiro and Senapathy weight matrix (66).
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splice-site match to consensus, with the score increasing
from 70.3 to 82.7 (Table 2).
We tested experimentally the splicing strengths of
the wild-type and mutant GHR pseudoexon 5 splice
sites. It was possible that that the wild-type pseudo-
exon 5 splice-site is intrinsically defective and is
therefore sufficient for pseudoexon suppression. We
studied the pseudoexon 5 splice sites in isolation
from the GHR pre-mRNA by using the human -globin
splicing reporter SP64-H6-IVS1–1A (thal) (22) (Fig.
1A). The thal reporter was chosen because it is a
sensitive and well-characterized 5 splice-site re-
porter. A 5 splice-site mutation in the thal exon leads
to use of an upstream cryptic 5 splice site. This gives
a mRNA product of 351 nucleotides rather than the
367 nucleotide mRNA of the reporter containing the
native 5 splice site (22). We replaced the thal 5 splice
site with GHR wild-type (thal-wt) and mutant (thal-mt)
5 splice sites (Fig. 1A) and performed in vitro splicing
assays. Both the wild-type and mutant GHR pseudo-
exon splice sites underwent equivalent splicing in the
thal context (Fig. 1B, lanes 7 and 10) and a comparison
of the mRNA size in Fig. 1B showed an increased
mRNA length in thal-wt and thal-mt compared with
thal (lanes 7 and 10 vs. 4). These data showed that
both wild-type and mutant GHR pseudoexon splice
Fig. 1. The Wild-Type Pseudoexon 5 Splice-Site Is Used Efficiently in a Different Context
A, Diagrammatic representations of the constructs used in the experiments are shown with the numbers beneath the exons
(boxes) and introns (lines) representing length in nucleotides. Thal is the previously described human -globin derived construct,
SP64-H6-IVS1–1A (22). Thal-wt and thal-mt are constructs with the thal nine-nucleotide 5 splice site (3 to 6) replaced by
the GHR wild-type or mutant pseudoexon splice-site, respectively. wt-L2 and mt-L2 are constructs with the GHR pseudoexon
attached to the L2 exon of AdML-par, derived from the previously described L1-wt-L2 and L1-mt-L2 constructs [AdML- and
AdML-mt in (19)]. L1-wt-L279–98 and L1-mt-L279–98 are constructs with 20 nucleotide deletions (79–98 in the example)
from within the pseudoexon sequence. AdML-par is as previously described (59) and AdML-par79–98 is AdML-par with the
79–98 silencer element tagged onto the 3 end of AdML exon L2. The last diagram represents the other pseudoexon constructs
with the relevant pseudoexon (-gal, 57 nucleotides; ATM, 69 nucleotides; BRCA1, 66 nucleotides; and PHEX, 51 nucleotides)
and 20 nucleotides of downstream intron attached to AdML exon L2 and its upstream intron. The final construct, C, is not shown
but is as previously described (25). Throughout the figures, AdML-derived exons are filled in black, GHR pseudoexon derived
exons are shaded gray and outlined with a dotted line, and thal-derived exons are unfilled. B, In vitro splicing for the wild-type
and mutant pseudoexon nine-nucleotide 5 splice sites in the context of the thal splicing reporter. Diagrammatic representations
of the pre-mRNAs and mRNAs are shown at the side of the panel. The mRNA with cryptic splice-site usage is shaded gray, and
the mRNA with true splice-site usage is unfilled. The other splicing-dependent bands are lariat intermediates and lariat products.
Lane 1 shows the standard Msp 1 digest of pBR322 run as a marker. C, In vitro splicing for the wild-type and mutant pseudoexon
5 splice sites in their native contexts. These constructs are as previously described (19) without the AdML-par L1 exon and intron.
As in Fig. 1B, diagrammatic representations of the pre-mRNAs and mRNAs are shown at the side of the panel. The other
splicing-dependent bands are lariat intermediates and lariat products.
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sites had intrinsic splicing activity and that this activity
was greater than that of the reporter cryptic splice site.
Silencing Elements within the Pseudoexon
Determine Skipping
We next determined the splicing effects of other se-
quences in the GHR pre-mRNA. We exploited in vitro
splicing assays using chimeric pre-mRNAs. We used
only the GHR pseudoexon and its splice sites in a
construct containing the adenovirus major late (AdML)
intron and L2 exon (wt-L2 and mt-L2 in Fig. 1A).
Note that the wild-type and mutant GHR pseudoexon
5 splice sites now lie in a limited native context, with
the complete GHR pseudoexon sequence, 54 nucle-
otides of upstream intron and 35 nucleotides of down-
stream intron. There remained a significant difference
(P  0.003) between the splicing of the wild-type and
mutant GHR pseudoexons (Fig. 1C, lanes 4 vs. 8),
consistent with our previous data (19). This suggested
that the sequences determining silencing of the GHR
pseudoexon were active when the GHR pseudoexon
was the leading exon and that they were confined to
the GHR pseudoexon itself and/or a limited range of
the surrounding introns. We also removed the GHR
upstream and downstream introns and in vitro splicing
experiments showed these had no effect on splicing
(data not shown). This implied that the splicing behav-
ior of the GHR pseudoexon is controlled via elements
within the pseudoexon itself.
To systematically test for regulatory elements, a se-
ries of 20 nucleotide deletions were made along the
length of both the wild-type and mutant pseudoexons
(L1-(wt/mt)-L2  79–98 is the example in Fig. 1A).
These pseudoexons with deletions were assessed for
splicing as the middle exon of the AdML-par splicing
reporter (Fig. 2A). Note that the deletions were of the
same length, thus acting as internal controls for non-
specific effects of GHR pseudoexon length on splicing
efficiency. Inclusion of the wild-type GHR pseudoexon
was seen when nucleotides 79–98 were deleted (Fig.
2A, lane 3 vs. lanes 1 and 9). This suggested a silenc-
ing element but one that only functioned with the
wild-type GHR pseudoexon splice-site and had no
silencing effect on the mutant GHR pseudoexon (com-
pare lane 4 vs. lanes 2 and 10). Traces of GHR pseudo-
exon inclusion were seen when nucleotides 39–58
(lane 7 vs. 1) and nucleotides 59–78 (lane 5 vs. 1) were
deleted. Deletion of nucleotides 3–18 had no effect on
splicing (data not shown). With the 79–98 deletion
there was also an increase in the wild-type pseudo-
exon skipped product (Fig. 2A, lane 3 vs. 1), suggest-
ing that the 79–98 silencer element (when active in the
wild-type context), also suppressed splicing generally
between AdML-par exons L1 and L2.
The amount of wild-type GHR pseudoexon splicing
was quantified. Figure 2B demonstrates that there was
a 4-fold increase in the ratio of GHR pseudoexon
splicing when the 79–98 element was deleted (P 
0.005). Figure 2C shows a diagram of the wild-type
GHR pseudoexon with the 39–58 and 79–98 silencing
elements and their nucleotide sequences denoted be-
neath. These silencing elements do not appear to re-
semble previously described or predicted silencing
elements (17, 23, 24). Furthermore, when the GHR
pseudoexon was assessed using FAS-ESS (http://
genes.mit.edu/fas-ess/) (24), the only predicted splic-
ing silencers occurred in the 19–38 region, which did
Fig. 2. Silencing Elements Occur within the Pseudoexon Se-
quence
A, In vitro splicing, at 1 h, for wild-type (wt) and mutant (mt)
pseudoexons in the context of the AdML-par splicing re-
porter. A series of 20 nucleotide deletions were made along
the length of the pseudoexons as represented by the dia-
grams above. The pre-mRNA, three exon mRNA, and two
exon mRNA are represented by diagrams to the left of the
panel. The pre-mRNAs and three exon mRNAs of the deletion
containing pseudoexons are 20 nucleotides smaller than the
full-length constructs in lanes 1 and 2. The other splicing-
dependent bands are lariat intermediates and lariat products.
B, The statistical analysis of the 79–98 deletion construct
compared with full-length control from five experiments. The
ratio of pseudoexon inclusion to skipping was analyzed using
the NIH (Bethesda, MD) Image program for quantitative as-
sessment. Two-tailed paired t test gave P  0.005. C, Dia-
gram of the pseudoexon with the principal silencing elements
portrayed as black boxes. The 20 nucleotides that contain the
silencers are shown beneath the diagram. D, In vitro splicing
for AdML-par and AdML-par79–98 where the 79–98 silenc-
ing element has been placed on to the 3 end of AdML-par
exon L2. Diagrammatic representations of the pre-mRNAs
and mRNAs are shown at the side of the panel. The other
splicing-dependent bands are lariat intermediates and lariat
products.
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not show silencing activity (Fig. 2A, lanes 9 and 10).
The increased GHR pseudoexon splicing was not due
to a nonspecific effect of decreased pseudoexon
length because there was only minimal splicing with
deletion of sequences 59–78 and 19–38.
Lastly, we tested whether the GHR pseudoexon
78–98 element had a general effect on silencing splic-
ing. We positioned the element at the end of the sec-
ond exon of AdML-par, a similar strategy to the char-
acterization of the native exonic splicing silencer of the
 exon of the DNA ligase III gene (25). The element did
not have silencing activity when placed in this different
context (Fig. 2D, compare lane 6 vs. 3).
Heterogenous Nuclear Ribonucleoprotein
(hnRNP) E1 Interacts with the Pseudoexon
and Is Important for Pseudoexon Skipping
To determine the factors acting at the GHR pseudo-
exon, we performed immunoprecipitation experiments
with antibodies available in the lab against hnRNP A1,
hnRNP E1, SF2/ASF, U1A, U1–70k and Sm. The ability
of the antibodies to specifically coimmunoprecipitate
radiolabeled pre-mRNAs was tested under three dif-
ferent in vitro splicing conditions; presplicing; step 1;
and, splicing. Presplicing conditions were HeLa nu-
clear extracts held on ice, thereby allowing only the
nonspecific complex H to form, but not splicing com-
plexes E or A (13). Step 1 reactions were in HeLa
nuclear extracts with ATP omitted, but incubated at
30 C, thus allowing the formation of early E and A
splicing complexes, but blocking progression to
later splicing steps and splicing complexes B and C.
The splicing reactions were pre-mRNAs incubated
at 30 C in HeLa nuclear extracts with all splicing
reagents (26). Anti-maltose-binding protein (MBP)
antibody was used as a control for nonspecific im-
munoprecipitation. hnRNP E1 specifically bound the
GHR pseudoexon under presplicing conditions (Fig.
3A, lanes 7 and 8) when compared with the AdML-
par control (lane 6). Furthermore, this binding was
associated with GHR pseudoexon skipping because
hnRNP E1 binding was 58% greater (P  0.015) in
the wild-type pseudoexon compared with the mu-
tant pseudoexon (lane 7 compared with 8). Although
this interaction remained detectable under step 1
conditions (lanes 13 and 14), it was lost under splic-
ing conditions (lanes 10 and 11). The binding of
hnRNP E1 with the GHR pseudoexon was detect-
able but was 19% (P  0.03) weaker for the 79–98
pre-mRNAs, compared with full-length wild-type
and mutant pseudoexons (Fig. 3B; lanes 11 and 12
vs. 9 and 10). Control immunoprecipitation experi-
ments with the anti-MBP antibody showed no im-
munoprecipitation of pre-mRNA (lanes 3–5) and
good recovery of appropriately spliced products,
intermediates and pre-mRNA in the supernatant to
show accurate loading (lanes 1 and 2). Immunopre-
cipitation experiments with antibodies targeting
splicing factors hnRNP A1 and SF2/ASF did not
coimmunoprecipitate pre-mRNA (data not shown).
To confirm whether hnRNP E1 was a silencer of
wild-type pseudoexon splicing in vivo, RNA interfer-
ence (RNAi) experiments were performed with small
interfering RNA (siRNA) duplexes targeting the hnRNP
E1 mRNA (Fig. 4). Eukaryotic expression plasmids
containing the wild-type and mutant pseudoexons in
the AdML-par reporter were transfected into HeLa
cells and extracted RNA was assayed for splicing by
RT-PCR. Panel B shows partial, but incomplete,
knockdown of hnRNP E1 mRNA at 24 h (lanes 5–10)
using three different targeting siRNA duplexes (H1-
H3), when compared with siRNA-negative controls
(lanes 1–4) and siRNA specificity controls targeting the
Fig. 3. The Pseudoexon Binds hnRNP E1 under Presplicing
Conditions
A, Immunoprecipitations, with anti-hnRNP E1 antibody or
anti-MBP antibody as a control, were performed on splicing
reactions preincubated under different conditions; presplic-
ing (4 C), Step 1 (30 C, no ATP) or splicing (30 C). The
constructs used were AdML-par (Ad) as a two exon control
compared with wt-L2 and mt-L2. Recovered radiolabeled
pre-mRNAs were demonstrated by PAGE. Lanes 1 and 2
represent 10% of the MBP control supernatant as loading
controls (less pre-mRNA correlates with more efficient splic-
ing). Pre-mRNA and mRNA are represented by the diagrams
at the side of the gel. Lanes 3–5 show background RNA
recovery using the MBP control antibody with all three con-
structs and lanes 6, 9, and 12 represent negative controls
with the AdML-par construct and hnRNP E1 antibodies. wt,
Wild type; mt, mutant. B, Immunoprecipitations were re-
peated as above with the addition of the 79–98 wild-type
and mutant pre-mRNAs. Lanes 1–8 are the MBP splicing
supernatant loading controls and immunoprecipitation con-
trols. Lanes 9–16 show results of immunoprecipitation with
anti-hnRNP E1 antibodies for the 4 pre-mRNAs under pres-
plicing and splicing conditions.
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lamin A/C and insulin receptor genes (lanes 11–14).
Transfection of siRNA oligonucleotides to hnRNP E1
was associated with a 2.3-fold (P 0.0017) increase in
pseudoexon inclusion in the wild-type pseudoexon
mini-gene (panel C, lanes 5, 7, and 9 compared with
lanes 3, 11, and 13). For the statistical analysis, quan-
titation of pseudoexon inclusion was compared for
siRNA to hnRNP E1 against the siRNA controls (lamin
A/C and IR) because there was also a slight increase in
splicing seen with these controls. In HeLa cells, the
wild-type pseudoexon was included to a greater ex-
tent (lane 3) than the in vitro setting, but a splicing
difference was maintained as the mutant pseudoexon
was fully included (lane 4). No significant increase was
seen in the mutant pseudoexon, suggesting this was
not a general splicing effect. However, the splicing
efficiency of the wild-type pseudoexon pre-mRNAwas
increased overall with siRNA against hnRNP E1 lead-
ing to an increase in both two and three exon mRNAs.
This result was similar to the overall increase in splic-
ing seen with deletion of the 79–98 silencer in vitro
(Fig. 2A, lane 3). Protein knockdown by Western blot-
ting was not assessed as a significant proportion of
hnRNP E1 is cytoplasmic (27), and it remains possible
that the antibody would cross-react with the 90%
homologous protein, hnRNP E2. An additional control
RT-PCR for hnRNP E2 was, however, performed and
this showed no difference in hnRNP E2 mRNA levels
with successful hnRNP E1 knockdown (data not
shown). All of these effects were observed with a
siRNA concentration of only 67 nM.
U1 snRNP Interacts with the Pseudoexon in a
snRNA-Independent Way that Is Inversely
Correlated to Splicing
We next investigated the interaction of U1 snRNP with
pseudoexon-containing pre-mRNAs by immunopre-
cipitation in HeLa nuclear extracts. Immunoprecipita-
tions were performed using antibodies against U1
snRNP core proteins: U1A and U1–70k. U1A specifi-
cally bound pseudoexon-containing pre-mRNAs un-
der presplicing conditions (Fig. 5A, lanes 8 and 9). This
contrasted with the constitutive exons of AdML-par
which were only bound by U1A under splicing condi-
tions (lanes 7 vs. 10). These AdML-par control data are
consistent with the previously published experiments
in -globin (28).
Furthermore, as seen with hnRNP E1, the U1A bind-
ing was associated with GHR pseudoexon skipping
because binding was 28% (P  0.03) greater in the
wild-type pseudoexon compared with the mutant
pseudoexon. Preliminary experiments assessing U1A
binding to pseudoexons with the 79–98 silencer re-
moved did not show a significant reduction in U1A
binding.
Under Step 1 conditions, there was also pseudo-
exon binding of U1A (data not shown), although this
was less than under presplicing conditions as found
for hnRNP E1 (Fig. 3A, lanes 13 and 14). Immunopre-
cipitation of the U1–70k protein gave similar results
(Fig. 5B), as did immunoprecipitations with antibodies
against the snRNP component Sm (data not shown).
However, for U1–70k and Sm immunoprecipitations,
Fig. 4. hnRNP E1 Depletion Is Associated with Increased Pseudoexon Recognition
HeLa cells were transfected with pCG plasmids containing the wild-type (wt) or mutant (mt) pseudoexons within the AdML-par
reporter (lanes 3–14). siRNA duplexes were cotransfected to a final concentration of 67 nmol/liter (lanes 5–14). siRNA duplexes
included three siRNAs targeting three regions of the hnRNP E1 mRNA as multiplicity controls (H1, H2, and H3 in lanes 5–10).
siRNAs targeting lamin A/C and insulin receptor (IR) were used as specificity controls (lanes 11–14). A, RNA loading with the
principal ribosomal 28S and 18S bands labeled. The RNA was also quantified by spectrophotometry and input RNA corrected
before reverse transcription. B, RT-PCR for hnRNP E1 mRNA (258 nucleotides) at 24 h after transfection. C, Splicing products
for the pseudoexon plasmids with inclusion (214) or skipping (106). Lane M shows the DNA marker pBR322 Msp I. Lane 1 shows
a no transfection control and lane 2 an oligofectamine alone control. Lanes 3 and 4 show plasmid transfection alone with no siRNA
cotransfection.
2534 Mol Endocrinol, October 2007, 21(10):2529–2540 Akker et al. • GHR Pseudoexon Splicing Suppression
 at Imperial College London (Royal Brompton Campus) on January 5, 2009 mend.endojournals.orgDownloaded from 
AdML-par was not immunoprecipitated under splicing
conditions, suggesting that the antibody binding site is
inaccessible. The U1–70k and Sm antibodies have
principally been used for snRNP immunoprecipitation
rather than snRNP/pre-mRNA coimmunoprecipitation.
UV cross-linking studies (Fig. 5C) showed that U1
snRNA only cross-linked to the mutant pseudoexon
(lane 6 vs. 2) (P  0.028) under splicing conditions
(lane 6 vs. 5). No cross-linking was seen under pres-
plicing conditions and depletion of U1 snRNA resulted
in loss of cross-linking to the mutant pseudoexon (lane
7 vs. 6).
U1 snRNP Undergoes a Pre-Spliceosomal
Interaction with Other Pseudoexons
To test whether pre-spliceosomal binding of U1
snRNP occurs in other pseudoexons and alternative
exons, immunoprecipitation experiments were per-
formed in extracts mixed with pre-mRNAs on ice. The
immunoprecipitating antibody was to U1A as in Fig.
5A. The test pre-mRNAs were: two rarely used alter-
native exons derived from the  galactosidase (29) and
DNA ligase III (25) genes; and, three other pseudoex-
ons with naturally occurring disease causing muta-
tions derived from the ATM (18), PHEX (30), and
BRCA1 (31) genes. AdML-par pre-mRNA was used as
a negative control because this contains a constitutive
intron efficiently interacting with U1 snRNP only under
full splicing conditions (Fig. 5A, lane 10) but weakly
under pre-spliceosomal conditions (Fig. 5A, lane 7).
Bacterial kanamycin resistance mRNA was used as an
intronless negative control RNA to show nonspecific
binding. Figure 6A shows that all the exons and
pseudoexons tested had increased binding of U1A
compared with AdML-par pre-mRNA and bacterial
kanamycin resistance mRNA controls. In two of the
three examples (GHR and ATM) where the naturally
occurring mutations were compared with the native
exon, U1A binding was reduced in the splicing active
context (lanes 5 vs. 4 and 9 vs. 8).
DISCUSSION
Numerous pseudosites within introns are actively sup-
pressed (15–18). The GHR pseudoexon has provided
a model with which to explore pseudoexon suppres-
sion. Our analysis indicated poor pseudosite and
pseudoexon prediction by bio-informatic criteria. The
finding that the wild-type GHR pseudoexon 5 splice-
site was capable of efficient splicing when placed in a
constitutive exon suggested the repressive influence
of other sequences in the pseudoexon. The deletion
experiments showed that the wild-type 5 splice-site
suppression is, in part, due to the presence of silenc-
ing elements within the pseudoexon. Silencing ele-
ments in proximity to the pseudoexon have been de-
scribed for both the hprt (15) and ATM (18)
pseudoexons, but the GHR pseudoexon 79–98 ele-
ment was surprising in that it appeared to only have an
effect on wild-type but not mutant pseudoexon splic-
Fig. 5. Wild-Type (wt) and Mutant (mt) Pseudoexons Bind
U1A under Presplicing Conditions but Only the Mutant
Pseudoexon Binds U1 snRNA
A, Immunoprecipitation assays, with anti-U1A antibody were
performed, as for Fig. 3, under either presplicing or splicing
conditions. The constructs used were AdML-par (Ad) as a two
exon control compared with wt-L2 and mt-L2. Lanes 1–3
represent 10% MBP loading controls. The MBP controls were
performed under presplicing conditions. Lanes 4–6 show RNA
recovery with anti-MBP antibodies and lanes 7–12 show results
for anti-U1A antibody under presplicing and splicing conditions.
B, Immunoprecipitation assays, with anti-U1 70k antibody were
performed, as for Fig. 5C, except that the MBP controls in this
experiment were performed under splicing conditions. The di-
agrams to the left represent the pre-mRNA andmRNA products
of the splicing supernatant. C, Pre-mRNA/snRNA UV cross-
linking was performed under step 1 conditions. Wild-type (lanes
1–4) and mutant (lanes 5–8) pseudoexon-containing pre-mR-
NAs (wt-L2 and mt-L2) were incubated in a step 1 splicing
assay (30 C, without ATP) except lanes 1 and 5 that were
incubated under presplicing conditions (4 C). Nuclear extracts in
lanes 3 and 7were preincubatedwith oligonucleotides targeting
the U1 snRNA as a U1 snRNA specificity control and extracts in
lanes 4 and 8were preincubatedwith oligonucleotides targeting
the U2 snRNA.
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ing. We acknowledge that deletion mutants may cre-
ate new hybrid sequences that might influence splic-
ing. However, the specific effect of the GHR
pseudoexon 79–98 on the splicing of the wild-type
pseudoexon but not on the mutant suggests a new
hybrid enhancer interaction is unlikely.
hnRNP E1 interacted with the GHR pseudoexon
under presplicing conditions in a manner that is in-
versely related both to splicing itself and splicing con-
ditions. Thus, the interaction was greater in the wild
type than in the mutant, and the protein bound to the
pre-mRNA only significantly on ice, with the immuno-
precipitation diminishing as the conditions are brought
closer to splicing ones (first in an extract halted at step
1, then a full splicing extract). The loss of detectable
hnRNP E1 under splicing conditions would be com-
patible with the known role of SR proteins and hnRNPs
in recruiting additional factors (see review in Ref. 14).
For example, one speculation is that recruitment of
additional factors rapidly occurs, thereby displacing
hnRNP E1. The RNAi results support a role for hnRNP
E1 in silencing of the GHR pseudoexon. Knockdown
of hnRNP E1 leads to an increase in splicing of wild-
type pseudoexon-containing pre-mRNAs with no in-
crease seen in mutant pseudoexon-containing pre-
mRNAs. If the knockdown of hnRNP E1 led to a
nonspecific increase in splicing, one would predict an
increase in the mutant pseudoexon-containing mRNA
also. We acknowledge that RNAi of hnRNP E1 in vivo
showed a wider increase in splicing activity than the in
vitro experiments, which may reflect undefined differ-
ences in the RNA reporters or cell constituents. Fur-
thermore, we acknowledge that there are considerable
technical difficulties in RNAi of hnRNP E1 and hnRNP
proteins in general. The difficulties reflect their nuclear
abundance, the lack of complete knockdown by
siRNA and their binding to multiple sites, as typified by
hnRNP A1 (32). hnRNP E1 transfection post-siRNA
and experiments with 79–98 silencer-deleted pseudo-
exons could provide more powerful evidence of
hnRNP E1 involvement, but we believe the current
data do partly support the in vitro data. hnRNP E1 (also
termed PCBP 1 and CP 1) has roles in translation and
mRNA stability and is found in both the nucleus and
cytoplasm (see Ref. 27 for review). It does, however,
colocalize in nuclear speckles with the splicing factor
SC35, suggesting a possible role in splicing (33).
The U1A immunoprecipitation data suggested that
U1 snRNP was also interacting with both wild-type
and mutant pseudoexons before expected spliceo-
some formation and, as with hnRNP E1, the interaction
was inversely correlated to splicing conditions. How-
ever, the interaction of U1 snRNP with the wild-type
pseudoexon was biochemically distinct from the char-
acteristics of its interaction with true exons. For true
exons (for example AdML-par, in Fig. 5A), U1 snRNP
bound the 5 splice-site in splicing extracts at 30 C,
before the need for ATP, but not while the in vitro
reactions were on ice (28). This unexpected pre-spli-
ceosomal interaction occurred in the five other
pseudoexons or rarely used alternative exons that
were tested. As with hnRNP E1, the U1 snRNP inter-
action was not detectable in the pseudoexons under
splicing conditions and we hypothesize that this is due
to either, displacement of the U1 snRNP by another
complex or recruitment of other factors around the U1
snRNP.
The U1 snRNA/5 splice-site interaction is an impor-
tant part of accurate and specific splicing (34). Splicing
is significantly reduced with U1 snRNA depletion, but
Fig. 6. U1 Interacts with Other Pseudoexons and Alternative
Exons under Presplicing Conditions
A, Immunoprecipitation assays, with anti-U1A antibody,
were performed against a panel of different pre-mRNAs un-
der presplicing conditions. Negative control constructs in-
cluded the bacterial kanamycin resistance gene (Kan) in lane
1 and AdML-par (Ad) in lane 3. Wild-type and mutated pre-
mRNAs are shown for the first three exons, the GHR pseudo-
exon [wild-type (wt) and mutant (mt)], the -galactosidase
alternative exon (-gal w and m) and the Ataxia Telangectasia
pseudoexon (ATM w and m). Wild-type pre-mRNAs only are
shown for the BRCA1 pseudoexon, the PHEX pseudoexon
and the DNA ligase III alternative exon (C). B, The upper
diagram represents the U1 snRNP interaction with a true 5
splice-site. The U1 snRNA is represented by the letters be-
tween the U1 snRNP and the 5 splice-site. The lower dia-
gram shows a model of pseudoexon repression where a
hnRNP interacts with a silencing element and U1 snRNP to
identify the 5 pseudo-site. A different conformation of U1
snRNP is represented by the changed shading and diversion
of the snRNA from the 5 splice-site. The U1 snRNA does not
base-pair with the pseudo-site and spliceosome formation is
blocked. This hnRNP/U1 snRNP/pre-mRNA interaction oc-
curs early, before possible spliceosome formation. A, Ade-
nine; G, guanine; U, uracil.
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U1 snRNP is still capable of interacting with 5 splice
sites both in yeast (35) and in mammals (34, 36). That
U1 snRNP may act as a suppressor of pseudoexon
splicing is plausible because it is recognized that U1
snRNP can act in an inhibitory manner. In mammals,
proximity of 5 consensus splice sites inhibits splicing
(28, 37, 38), and there are several models in which U1
snRNP is proposed to have an inhibitory role. Exonic
splicing enhancers are known to encourage U1 snRNP
binding to genuine 5 splice sites (28, 39) but work on
the Drosophila P-element shows that, in a contrasting
manner, U1 snRNP may bind pseudosites, together
with silencers, to actually disrupt splicing at the gen-
uine 5 splice-site. This allows regulation of alternative
splicing of the P-element third intron (40). Similar work
demonstrates that U1 snRNP also has a role in the
skipping of a pseudoexon within intron 20 of the ATM
gene (18). Finally, a U1 snRNP complex has been
shown to bind 5 pseudosites within viral negative
regulatory elements of the Rous sarcoma virus (41)
and the human papilloma virus type 16 (42). Interest-
ingly hnRNP E1 has been shown to also bind the same
region of the human papilloma virus 16 mRNA (43).
The data above would support the previously de-
scribed models of 5 splice-site selection (44, 45) to
include pseudosites. Thus, for 5 pseudosites, inhibi-
tory splicing factors act to destabilize the potential U1
snRNA/5 splice-site interaction. Early, pre-spliceoso-
mal binding (complex H) of the silencers and U1
snRNP would ensure that these sites are safely iso-
lated. U1 snRNP binding may be in a different config-
uration. The cross-linking data (Fig. 5C) could be ex-
plained if this were the case. Cross-linking of the U1
snRNA to the pre-mRNA was only seen in the mutant
under STEP 1 conditions, as would be predicted if the
U1 snRNA/pre-mRNA interaction is a prerequisite to
splicing. The presplicing U1A immunoprecipitations
(Fig. 5A) suggest that there was a U1 snRNP/pre-
mRNA interaction, but the lack of cross-linking in both
wild-type and mutant pre-mRNAs under presplicing
conditions suggested that this interaction is indeed
different.
Figure 6B is a diagrammatic model of this potential
U1 snRNP interaction. The upper diagram shows the
U1 snRNP interacting with an active 5 splice site
(such as the mutant pseudoexon). The U1 snRNA base
pairs with the 5 splice site and recruits the spliceo-
some. The lower diagram shows the pseudoexon si-
lencer interacting with the 5 splice site. The interac-
tion leads to the early recruitment of a hnRNP and U1
snRNP. However, the U1 snRNP does not interact in
an active conformation, and thus blocks further re-
cruitment of spliceosomal factors. By temporally en-
suring that this inhibitory U1 snRNP role occurs before
active U1 snRNP interactions, splicing fidelity is main-
tained. The model is likely to be an over simplification
because our data suggest the presence of more than
one silencing element (Fig. 3A) and more than one
hnRNP E1 binding site (Fig. 4B). One possibility is that
cooperative binding of other silencing factors would
follow an initial interaction. This model would be the
mammalian equivalent of that proposed for the Dro-
sophila P-element, which also does not require base
pairing between the U1 snRNA and target pre-mRNA
(40). There is some further published evidence to sup-
port such a role for hnRNPs and U1 snRNP: 1) It has
previously been demonstrated that hnRNP A1 leads to
decreased U1 snRNA/pre-mRNA base pairing (46–48);
2) Several systematically identified exonic splicing si-
lencers are also 5 pseudosites (24); and 3) U1 snRNP
is the most abundant snRNP, with twice the number of
copies per cell when compared with U2 snRNP and
five times the copies of U4 and U5 snRNPs (49). These
data suggest a potential additional role of a U1 snRNP/
hnRNP interaction to identify and isolate potential 5
splice sites. Our data also suggest that a defect in the
mechanism of suppression of pseudoexon splicing
could result in GHR pseudoexon inclusion and Laron
syndrome. There may well be other similar examples
of intronic mutations leading to removal of pseudo-
exon suppression, and resulting in genetic disease.
MATERIALS AND METHODS
Construction of Pre-mRNA Templates
Templates were made as described (19) by overlap extension
PCR. Oligonucleotide sequences are available on request.
Radiolabeled pre-mRNAs were transcribed with SP6 or T7
RNA polymerase using [-32P-GTP] and then gel purified.
Splicing Reactions
The 25-l splicing reactions were performed using 20 fmol of
pre-mRNA, incubated with HeLa cell nuclear extract splicing
mix as described (50), under presplicing (0 C), Step 1 (30 C
but without ATP) or splicing (30 C) conditions.
Immunoprecipitations
Anti-MBP antibodies (51) and anti-U1 70k (2.73) antibodies
(52) were kindly provided by Adrian Krainer (Cold Spring
Harbor Laboratory, Cold Spring Harbor, NY). Anti-U1A (1E1)
antibodies (53) were kindly provided by J. Alwine (University
of Pennsylvania, Philadelphia, PA) and anti-hnRNP E1
(GSTE1) antibodies (54) by Asok Antony (Indiana University,
Indianapolis, IN). Experiments were essentially performed as
described (50). Briefly, Protein G Sepharose beads (Amer-
sham Biosciences, Buckinghamshire, UK) were washed and
incubated overnight at 4 C with antimouse or, for GSTE1,
antirabbit IgG. After three further washes in buffer IP150, the
specific antibodies were then prebound for 2 h at 4 C. After
three further washes, 25-l splice reactions with 475 l IP150
buffer were added and incubated for 1 h at 4 C. The final three
washes were performed with IP150 buffer containing 0.5
mg/ml tRNA. The resuspended pellet underwent phenol ex-
traction and ethanol precipitation.
RNAi Cotransfections
Three siRNAs targeting hnRNP E1 mRNA were selected us-
ing recognized criteria (55) from a list generated by the Dhar-
macon on-line siRNA design center, after a BLAST search
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(H1; AAGAGATCCGCGAGAGTAC, H2; CTCGATTCAAGGA-
CAACAC, H3; CTTAATTGGCTGCATAATC). siRNAs targeting
the insulin receptor and Lamin A/C mRNA were ordered as
specificity controls. Mini-gene systems expressing wild-type
or mutant pseudoexons were made by subcloning the de-
scribed AdML-par pseudoexon constructs (19) into pCG
plasmids. HeLa cells were seeded in 24-well plates at a
concentration of 100,000/ml in a final volume of 0.5 ml. Cells
were treated at 24 h with siRNA, using transfection protocols
previously described (56, 57), with the following changes:
siRNA was added to a final concentration of 67 nM and was
cotransfected with 1 g of the wild-type or mutant pseudo-
exon mini-gene. Previous titration experiments had estab-
lished the minimum effective dose to knock down hnRNP E1
expression with minimal cell toxicity.
RNA was harvested from cells 24 h after transfection using
the QIAGEN (Sussex, UK) RNeasy kit as per the manufactur-
er’s instructions. The RNA was subjected to an additional
deoxyribonuclease digestion step using ribonuclease-free
RQ1DNase enzyme (Promega, Southampton, UK). RT-PCR
was performed, with equal RNA loading (400 ng/reaction)
ensured by standardization of concentrations using spectro-
photometric readings. cDNA was subjected to PCR assaying
for hnRNP E1 mRNA, hnRNP E2 mRNA and GHR pseudo-
exon splicing products.
UV Cross-Linking Studies
Step 1 splicing reactions were preincubated, for 15 min at 30
C, with 1 l oligonucleotide (400 M) complementary to the
U1 or U2 snRNA as previously described (58), before adding
20 fmol RNA. Ten microliters of each 25-l reaction were then
added to 0.4 l of ATP/CP and standard splicing control
reactions were performed to ensure satisfactory U1/U2 de-
pletion (data not shown). The remaining 15-l reactions were
incubated at 30 C for 30 min and then, on ice, exposed to
9000J  2 of UV light. Fifty microliters of Proteinase K mix
were added and each reaction incubated for 15 min at 37 C.
Samples were then phenol extracted, ethanol precipitated
and visualized by PAGE.
Statistical Analyses
High resolution scans of the SDS-PAGE gels were quantified
using Fujifilm (Tokyo, Japan) Multigauge version 2.3 soft-
ware. GraphPad (San Diego, CA) prism software was used to
analyze the data and the P values stated are the results of
two-tailed t tests.
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